Evaluation of the protein biomarkers and the analgesic response to systemic methylene blue in patients with refractory neuropathic pain: a double-blind, controlled study (2015)

Peer-Reviewed Study · Miclescu AA, Svahn M, Gordh TE · July 15, 2015

Miclescu AA et al., 2015-07-15: Small double-blind controlled study of intravenous methylene blue in refractory neuropathic pain, finding a pain reduction on the first two days after infusion. The only controlled human IV-MB pain study located, and it is 10 patients.

MB decreased the pain levels in patients with chronic therapy-resistant neuropathic pain on the first 2 days after administration. Known as an endocrine modulator on the anterior pituitary gland, MB infusion produced

Miclescu AA et al., 2015-07-15: Small double-blind controlled study of intravenous methylene blue in refractory neuropathic pain, finding a pain reduction on the first two days after infusion. The only controlled human IV-MB pain study located, and it is 10 patients. Study type: double-blind controlled study (low-dose control). N=10. Country: Sweden (Uppsala). MB 2 mg/kg versus 0.02 mg/kg infused over 60 min, intravenous. Funding/conflicts: not stated in record. Comparator: subtherapeutic MB dose (0.02 mg/kg), not placebo. Outcome: NRS fell at 60 min and differed between groups on day 0 and day 1; effect gone by day 2-5. Supports rapid but short-lived IV relief only. Also filed as MTD-075 (claims C10, C12).